Home/Filings/4/0001104659-21-112499
4//SEC Filing

Kraus Al 4

Accession 0001104659-21-112499

CIK 0001175151other

Filed

Sep 1, 8:00 PM ET

Accepted

Sep 2, 4:31 PM ET

Size

9.5 KB

Accession

0001104659-21-112499

Insider Transaction Report

Form 4
Period: 2021-08-31
Kraus Al
Director
Transactions
  • Exercise/Conversion

    Stock Option (right to buy)

    2021-08-314,0000 total
    Exercise: $4.13From: 2012-01-18Exp: 2022-01-18Common Stock (4,000 underlying)
  • Exercise/Conversion

    Common Stock

    2021-08-31$4.13/sh+4,000$16,500129,046 total
  • Sale

    Common Stock

    2021-08-31$9.40/sh4,000$37,591125,046 total
Footnotes (2)
  • [F1]Reflects the weighted average price of sales on August 31, 2021. The shares were sold in multiple transactions at prices ranging from $9.38 to $9.409, inclusive. The reporting person undertakes to provide to CytoSorbents Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  • [F2]Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 55,746 shares of common stock owned by the reporting person.

Issuer

Cytosorbents Corp

CIK 0001175151

Entity typeother

Related Parties

1
  • filerCIK 0001368152

Filing Metadata

Form type
4
Filed
Sep 1, 8:00 PM ET
Accepted
Sep 2, 4:31 PM ET
Size
9.5 KB